secwatch.observer — SEC 8-K summary
======================================

Issuer:     LB PHARMACEUTICALS INC (LBRX)
CIK:        0001691082
Form:       8-K
Filed at:   2026-03-26T23:59:59+00:00
Accession:  0001193125-26-126223
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LB Pharmaceuticals reports Q4 net loss $11.5M; cash $295.2M; advances LB-102 into Phase 3
--------------------------------------------------------------------------------

- Positive Phase 2 (NOVA-1) results for LB-102 in acute schizophrenia met primary endpoint; Phase 3 NOVA-2 initiated March 2026 with data expected H2 2027.
- Phase 2 ILLUMINATE-1 trial in bipolar depression started Jan 2026; Phase 2 for adjunctive MDD planned early 2027.
- September 2025 IPO raised $327.8M (21.85M shares at $15); February 2026 private placement added $100M.
- Cash and investments $295.2M at Dec 31, 2025; with private placement, runway into Q2 2029.
- Q4 2025 net loss $11.5M ($5.1M Q4 2024); full-year net loss $25.2M ($63.1M 2024); R&D expenses declined YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/0001193125-26-126223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/d129775d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-126223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer